Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

Recurrent MR after TEER: Tracking data from nearly 700 MitraClip patients

The new analysis focused on both primary and secondary MR 12 months after TEER. 

Thumbnail

Abbott implantable heart failure monitor gains expanded FDA approval

An estimated 1.2 million additional patients are now candidates for the company's small CardioMEMs HF monitor. 

healthcare value value-based care money dollar

Boston Scientific finalizes acquisition of Baylis Medical with $1.75B payment

The deal, first announced in October 2021, expands Boston Scientific’s structural heart disease and electrophysiology portfolios by a significant margin. 

Part of the cath lab case report from Fujifilm Synapse Cardiovascular. This CVIS was ranked Best in KLAS in 2022 based on user interviews.

Best of KLAS 2022: The top cardiovascular information systems and hemodynamic solutions

KLAS Research released its 2022 Best in KLAS report, which includes cardiovascular information systems and hemodynamic systems. 

Ticagrelor alone after DAPT lowers bleeding risk among heart attack patients undergoing PCI

Researchers examined data from the TWILIGHT study to track how different treatment strategies can impact 12-month PCI outcomes. 

New risk score predicts mortality after TEER

Researchers developed the new algorithm by identifying eight key factors associated with mortality among TEER patients. 

The Bard Venovo venous stent

Office-based cath lab setting proves safe for iliac vein stenting

Iliac vein stunting procedures performed in out-patient office-based labs are associated with low complication rates.

Polymer-free amphilimus-eluting stents comparable to drug-eluting stents—and offer a potential advantage

The team's evaluation included data from four different randomized controlled trials